All enpatoran dosages were associated with improvements in skin manifestations of cutaneous lupus erythematosus and systemic ...

Previous STI history is linked to increased current PrEP use, though uptake disparities remain across patient demographic groups.

Patients with moderate to severe plaque psoriasis who received any dosage of SHR-1139 had improvements in skin clearance at ...

Izokibep was effective in reducing disease activity among patients with HS, including those who switched to izokibep from ...

Dupilumab use among pediatric patients with moderate to severe AD is associated with a meaningful increase in weight ...

Women who deliver preterm have lower vitamin D concentrations than women who deliver at term, according to recent study results.

An investigational therapy, SSGJ-608, was associated with substantial skin clearance through 52 weeks among patients with plaque psoriasis.

Patients with NF1 have a greater prevalence of cherry angiomas than the general population and NF1 inactivation may contribute to their development.

The Food and Drug Administration expanded the approval of baricitinib to include those aged 12 years and older.

The FDA has updated labeling for Kybella (deoxycholic acid) to warn clinicians of persistent nodules, masses, and adverse events linked to off-label use.

Patients with psoriasis who used biologic therapies had a lower risk for incident psoriatic arthritis than those who were biologic-naive.

Amgen’s phase 3 OASIZ 301 trial shows dazodalibep significantly improves systemic disease activity in adults with moderate to severe Sjögren disease at week 48.